
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc. is positioned favorably due to its focus on developing innovative treatments in oncology and COVID-19, specifically its lead drug Endoxifen and two promising COVID-19 therapies, AT-H201 and AT-301. The company's current valuation is deemed attractive, supported by a recent adjustment in the price target reflecting a positive net present value analysis. Anticipated progress in key clinical milestones is expected to drive further investor interest and bolster the stock's potential.
Bears say
Atossa Therapeutics reported a net loss of $8.4 million, which translates to an earnings per share (EPS) of $(0.07), falling short of both internal and consensus estimates of $(0.06). The company's financial outlook is further compounded by a multitude of risks, including significant balance sheet and liquidity concerns, potential failures in clinical trials affecting product safety and efficacy, and challenges in obtaining regulatory approvals. Additionally, the landscape of biotechnology investments remains precarious, influenced by ongoing competition, shifting macroeconomic conditions, and changes in healthcare priorities, all of which could adversely affect the company's ability to commercialize its product candidates.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares